GHK plus Dalargin: 2011 bone-repair patent — RU2429002C1
Виктор Юрьевич Чердаков, Михаил Юрьевич Смахтин, Григорий Михайлович Дубровин, Игорь Иванович Бобынцев, Виктор Тарасович Дудка, Максим Евгеньевич Долгинцев, Алексей Анатольевич Крюков, Вадим Теймуразович Корошвили, Ирина Михайловна Соболева, Евгений Николаевич Кононец, Андрей Евгеньевич Белых, Ольга Игоревна Иванова · 2011 · RU2429002C1 · patent family 44758621
Published 2011-09-20.
Reported patent results
Narrative findings; numerical extraction incomplete
The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.
Wistar rat fracture model; groups of 8–10 animals; saline, copper-free GHK, Dalargin and combined treatment; assessment at day 10.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combined treatment: radiographic appearance | Fracture line described as barely visible with the combination; still visible but less pronounced with either peptide alone | Versus saline and single-peptide groups; no numerical radiographic score or uncertainty reported · Day 10 |
| Combined treatment: histological appearance | New bone formation and remodeling toward compact bone were described as more advanced in the combination group | Descriptive morphology; no quantitative histomorphometry or factorial interaction test · Day 10 |
| GHK versus Dalargin alone | No visible morphological difference reported between the two single-peptide groups | A neutral qualitative comparison, not a demonstration of equivalence · Day 10 |
| Healing time, strength and safety | No measured union-time advantage, biomechanical strength estimate or formal adverse-event series reported | A day-10 observation does not mean fractures healed ten days faster |
| Reported group sizes | 8–10 rats per group; exact group denominators not assigned | |
| Reported experimental course | Daily GHK plus Dalargin for ten days; other groups received single peptides or saline |
Early rat bone-repair observations do not establish clinical fracture healing or quantitatively validated synergy. The preparation was copper-free GHK plus Dalargin. Related author publications may reuse the research program.
Source for the extracted data ↗ · Checked 2026-11-07
Patent claims and provenance
Related 2021 journal paper: neutrophil results → — a local-delivery rat study; its numerical results are not measurements from this patent.
Use. The claim combines unbound Gly-His-Lys with Dalargin for reparative osteogenesis; rat radiographs and histology support the disclosed rationale.
Combination findings must not be assigned to GHK-Cu, Dalargin alone or human fracture healing. No measured shortening of healing time or biomechanical strength was reported.
- Publication
- RU2429002C1 ↗ · 2011-09-20
- Earliest priority / filing
- 2010-09-13 / 2010-09-13
- Original applicant / assignee
- Kursk State Medical University
- Indexed status
- IP Right Cessation — indexed historical event; official status unverified · checked 2026-11-07
- Patent family
- 44758621 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of stimulating reparative osteogenesis
Inventors: Виктор Юрьевич Чердаков; Михаил Юрьевич Смахтин; Григорий Михайлович Дубровин; Игорь Иванович Бобынцев; Виктор Тарасович Дудка; Максим Евгеньевич Долгинцев; Алексей Анатольевич Крюков; Вадим Теймуразович Корошвили; Ирина Михайловна Соболева; Евгений Николаевич Кононец; Андрей Евгеньевич Белых; Ольга Игоревна Иванова.
RU2429002C1 · RU2589264C2 · RU2589265C2 · RU2593817C2 · RU2676659C1 · WO2021211006A1 · US5367053A · RU2193868C2 · RU2195311C2 · WO2004106491A2 · RU2295969C1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Combination findings must not be assigned to GHK-Cu, Dalargin alone or human fracture healing. No measured shortening of healing time or biomechanical strength was reported.
- Early rat bone-repair observations do not establish clinical fracture healing or quantitatively validated synergy. The preparation was copper-free GHK plus Dalargin. Related author publications may reuse the research program.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-44758621. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-07. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Виктор Юрьевич Чердаков, Михаил Юрьевич Смахтин, Григорий Михайлович Дубровин, Игорь Иванович Бобынцев, Виктор Тарасович Дудка, Максим Евгеньевич Долгинцев, Алексей Анатольевич Крюков, Вадим Теймуразович Корошвили, Ирина Михайловна Соболева, Евгений Николаевич Кононец, Андрей Евгеньевич Белых, Ольга Игоревна Иванова. GHK plus Dalargin: 2011 bone-repair patent — RU2429002C1 RU2429002C1 · patent family 44758621 2011.
Molekul research summary: https://molekul.io/research/patent-ru2429002c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
GHK-Cu & GHK family
A single research family collecting GHK-Cu, unbound GHK, Russian terminal extensions, stereochemical variants and related delivery constructs. The member map identifies which molecule each source actually studied; a shared card does not establish interchangeable biological activity.
Dalargin
A Soviet synthetic opioid hexapeptide investigated in cytoprotection, stress, hypoxia, ischemia and trauma. Its enkephalin lineage is distinct from organ-derived peptide bioregulators; historical proposals and laboratory effects are not established clinical indications.